Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600527056> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W2600527056 endingPage "e13097" @default.
- W2600527056 startingPage "e13097" @default.
- W2600527056 abstract "e13097^ Background: The primary objective of this study was to compare catumaxomab with prednisolone (CP) to catumaxomab without prednisolone (C) as 3-hour intraperitoneal (i.p.) infusion by demonstrating superiority for safety and non-inferiority for efficacy of the CP arm. Methods: 219 patients were randomized to catumaxomab plus premedication of 25 mg prednisolone (111 pts) or to catumaxomab alone (108 pts). The primary endpoint was the composite safety score (CSS) summarizing the worst CTCAE grades for the main TEAEs (pyrexia, nausea, vomiting, and abdominal pain). A potential impact of prednisolone on efficacy was assessed by the co-primary endpoint puncture-free survival (PuFS). Further parameters included overall survival (OS) and time to next therapeutic puncture (TTPu). Results: The superiority of CP for safety was not proven as the mean CSS was comparable in the two groups (CP: 4.1; C: 3.8 for; p= 0.383). The median PuFS was slightly lower in CP (30 days) compared to C (37 days). However the hazard ratio (HR) for PuFS (HR: 1.130, p=0.402) as well as the 75% quartiles (CP: 155 days, C: 92 days) were in favour of CP compared to C. The median TTPu was similar in both groups (CP: 78 days; C: 102 days, p= 0.599). The majority of patients (123 pts) had no therapeutic paracentesis prior to death (CP: 54.8%; C; 61.7%, p=0.297). Median OS was longer for CP (CP: 124 days; C: 86 days, p= 0.186) without statistical significance. Conclusions: The CASIMAS results are in concordance with the data of the pivotal study and thus confirm the robustness of the treatment effect of catumaxomab in malignant ascites. The administration of 25mg prednisolone as premedication prior to catumaxomab infusion did not change the safety profile and did not negatively impact the efficacy of catumaxomab. The composite safety score after 3-hour infusion time was comparable to that seen in the pivotal study using 6 hours." @default.
- W2600527056 created "2017-04-07" @default.
- W2600527056 creator A5002555374 @default.
- W2600527056 creator A5005869893 @default.
- W2600527056 creator A5007237048 @default.
- W2600527056 creator A5011919158 @default.
- W2600527056 creator A5020893157 @default.
- W2600527056 creator A5025022676 @default.
- W2600527056 creator A5026048739 @default.
- W2600527056 creator A5031031537 @default.
- W2600527056 creator A5034247691 @default.
- W2600527056 creator A5050136275 @default.
- W2600527056 creator A5050467390 @default.
- W2600527056 creator A5058535647 @default.
- W2600527056 creator A5061218922 @default.
- W2600527056 creator A5063619703 @default.
- W2600527056 creator A5066888430 @default.
- W2600527056 creator A5072055304 @default.
- W2600527056 creator A5078383767 @default.
- W2600527056 creator A5082045927 @default.
- W2600527056 creator A5089392438 @default.
- W2600527056 date "2012-05-20" @default.
- W2600527056 modified "2023-10-03" @default.
- W2600527056 title "Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: Results from the phase IIIb CASIMAS study." @default.
- W2600527056 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.e13097" @default.
- W2600527056 hasPublicationYear "2012" @default.
- W2600527056 type Work @default.
- W2600527056 sameAs 2600527056 @default.
- W2600527056 citedByCount "1" @default.
- W2600527056 countsByYear W26005270562015 @default.
- W2600527056 crossrefType "journal-article" @default.
- W2600527056 hasAuthorship W2600527056A5002555374 @default.
- W2600527056 hasAuthorship W2600527056A5005869893 @default.
- W2600527056 hasAuthorship W2600527056A5007237048 @default.
- W2600527056 hasAuthorship W2600527056A5011919158 @default.
- W2600527056 hasAuthorship W2600527056A5020893157 @default.
- W2600527056 hasAuthorship W2600527056A5025022676 @default.
- W2600527056 hasAuthorship W2600527056A5026048739 @default.
- W2600527056 hasAuthorship W2600527056A5031031537 @default.
- W2600527056 hasAuthorship W2600527056A5034247691 @default.
- W2600527056 hasAuthorship W2600527056A5050136275 @default.
- W2600527056 hasAuthorship W2600527056A5050467390 @default.
- W2600527056 hasAuthorship W2600527056A5058535647 @default.
- W2600527056 hasAuthorship W2600527056A5061218922 @default.
- W2600527056 hasAuthorship W2600527056A5063619703 @default.
- W2600527056 hasAuthorship W2600527056A5066888430 @default.
- W2600527056 hasAuthorship W2600527056A5072055304 @default.
- W2600527056 hasAuthorship W2600527056A5078383767 @default.
- W2600527056 hasAuthorship W2600527056A5082045927 @default.
- W2600527056 hasAuthorship W2600527056A5089392438 @default.
- W2600527056 hasConcept C126322002 @default.
- W2600527056 hasConcept C141071460 @default.
- W2600527056 hasConcept C168563851 @default.
- W2600527056 hasConcept C203092338 @default.
- W2600527056 hasConcept C207103383 @default.
- W2600527056 hasConcept C2776715498 @default.
- W2600527056 hasConcept C2778300832 @default.
- W2600527056 hasConcept C2780496750 @default.
- W2600527056 hasConcept C2780580376 @default.
- W2600527056 hasConcept C2780852908 @default.
- W2600527056 hasConcept C44249647 @default.
- W2600527056 hasConcept C71924100 @default.
- W2600527056 hasConcept C90924648 @default.
- W2600527056 hasConceptScore W2600527056C126322002 @default.
- W2600527056 hasConceptScore W2600527056C141071460 @default.
- W2600527056 hasConceptScore W2600527056C168563851 @default.
- W2600527056 hasConceptScore W2600527056C203092338 @default.
- W2600527056 hasConceptScore W2600527056C207103383 @default.
- W2600527056 hasConceptScore W2600527056C2776715498 @default.
- W2600527056 hasConceptScore W2600527056C2778300832 @default.
- W2600527056 hasConceptScore W2600527056C2780496750 @default.
- W2600527056 hasConceptScore W2600527056C2780580376 @default.
- W2600527056 hasConceptScore W2600527056C2780852908 @default.
- W2600527056 hasConceptScore W2600527056C44249647 @default.
- W2600527056 hasConceptScore W2600527056C71924100 @default.
- W2600527056 hasConceptScore W2600527056C90924648 @default.
- W2600527056 hasIssue "15_suppl" @default.
- W2600527056 hasLocation W26005270561 @default.
- W2600527056 hasOpenAccess W2600527056 @default.
- W2600527056 hasPrimaryLocation W26005270561 @default.
- W2600527056 hasRelatedWork W192628228 @default.
- W2600527056 hasRelatedWork W1964830422 @default.
- W2600527056 hasRelatedWork W1973977319 @default.
- W2600527056 hasRelatedWork W2049216007 @default.
- W2600527056 hasRelatedWork W2054055106 @default.
- W2600527056 hasRelatedWork W2094386548 @default.
- W2600527056 hasRelatedWork W2233013265 @default.
- W2600527056 hasRelatedWork W2396419251 @default.
- W2600527056 hasRelatedWork W3119031272 @default.
- W2600527056 hasRelatedWork W2404732428 @default.
- W2600527056 hasVolume "30" @default.
- W2600527056 isParatext "false" @default.
- W2600527056 isRetracted "false" @default.
- W2600527056 magId "2600527056" @default.
- W2600527056 workType "article" @default.